Global Advanced Therapy Medicinal Products Market by Therapy Type (Cell, CAR-T, Stem Cell Therapy, Gene) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global advanced therapy medicinal products market was valued at USD 7.9 Billion in 2020. It is expected to grow at a compound annual rate (CAGR of 13.2%) between 2021 and 2028. Advanced Therapy Medicinal Products have revolutionized the pharmaceutical industry as well as the disease treatment landscape. This has opened up new avenues for treatment of incurable disease and many types of cancer. Market growth is largely due to the success of products like Kymriah and Zolgensma.
Advanced therapies in virology research have been applied to the COVID-19 pandemic. In December 2020, a study showed the potential for T cell therapy to treat high-risk COVID-19 patients. In September 2020, the U.S. FDA approved ALVR109, an allogeneic T cell therapy IND application, for COVID-19 patients.
This will drive investment in R&D for advanced treatment for SARS-CoV2 infection. As a new treatment for SARS-CoV-2, there has been a rise in Mesenchymal Stromal/Stem Cells clinical trials. These therapies have been proven to be effective in treating SARS-CoV-2 infection and are a great addition to the marketspace's organic revenue generation.
The market for advanced therapeutic medicinal products is still in its infancy, but it is growing. Traditional drug companies are looking to increase their competitive edge by considering ATMPs as a potential source of future revenue. This market is extremely active, and many companies have invested heavily in clinical trials for ATMPs after approval of their products.
Many protein- and small-molecule-based companies have been focusing their efforts on developing adoptive cell T therapies over the years. In March 2021, Bristol Myers Squibb and bluebird bio obtained approval from the FDA for Abecma (idecabtagene vicleucel), a cell-based gene-therapy medicinal product that is used to treat multiple myeloma patients.
Therapy Type Insights
With a 39.0% revenue share in 2020, the tissue-engineered products segment was the dominant market. This can be attributed to tissue-engineered products and procedures being integrated into medicine and treatment procedures, especially in cases that require functional restoration of diseased or injured parts of the body.
The remarkable rise in publications, clinical trials, research studies, and translational products has demonstrated that this segment is gaining traction. The segment's growth is also supported by continuous technological and product advancements that improve the tissue engineering process. A team of researchers from the University of Illinois Chicago created a new hydrogel-shaped-changing 4D material that can respond to physiological stimuli.
The CAR-T therapy sector, on the other hand is growing rapidly and will register the fastest CAGR during the forecast period. Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb, and Gilead Sciences, Inc. are all focused on expanding their CAR-T product reach across the globe. Novartis AG, for example, announced that the Health Sciences Authority approved Kymriah as Singapore's first CAR-T treatment.
Kymriah, a CAR–T product, is designed to treat patients with B-cell acute Lymphoblastic Leukemia (B-cell AML) and relapsed/refractory (r/r), diffuse large B-cell-cell lymphoma. Similar to Bristol Myers Squibb, Breyanzi, a CAR-T cell therapy that treats R/R B Cell Lymphoma, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW), in March 2021. This has led to significant growth in segments due to the shift in investment flow towards the development of CAR–T products.
Regional Insights
North America was the dominant market for advanced therapy medicinal products in 2020, accounting for 47.0% of the total revenue. The region's dominance in the advanced therapy market is due to its favorable regulatory environment, product launches that have been successful, and large investments in research and developing. The U.S. is seeing a rapid increase in clinical trials for this new treatment option, which also contributes to regional growth.
The U.S. currently accounts for approximately 57.0% in gene therapy clinical trials worldwide as of March 2021. This large share is a result of the growing investment flow into this market, which drives the revenue generation. Europe held the second largest market share in 2020 thanks to its strong research base in advanced therapies.
China has been ranked second in the world for cell and gene therapy markets in recent years. China has shown the highest CAGR in Asia Pacific thanks to its focussed efforts, including investments by the government and reforms.
Market Share Insights & Key Companies
In the last few years, there has been a tremendous increase in demand for advanced therapeutic medicinal products. This market will see increased competition due to the increasing number of companies entering the space. Recent approvals of ATMPs have also accelerated this expansion. Market players have a variety of strategies to maintain their market position. This space is seeing a lot of collaborations with contract manufacturers. Due to the increasing R&D activity in this space, CDMO/CMOs see a high demand for their services. The market for advanced therapy medicinal products (ATMPs), includes the following:
-
Spark Therapeutics, Inc.
-
Bluebird Bio, Inc.
-
Novartis AG
-
UniQure N.V.
-
Celgene Corporation
-
Gilead Lifesciences, Inc.
-
Kolon TissueGene, Inc.
-
JCR Pharmaceuticals Co., Ltd.
-
MEDIPOST
-
Vericel Corporation
-
PHARMICELL Company, Ltd
-
Organogenesis Inc.
Up Market Research published a new report titled “Advanced Therapy Medicinal Products Market research report which is segmented by Therapy Type (Cell, CAR-T, Stem Cell Therapy, Gene), By Players/Companies Organogenesis Inc, JCR Pharmaceuticals Co Ltd, Celgene Corporation, Novartis AG, UniQure NV, Kolon TissueGene Inc, Bluebird Bio Inc, Vericel Corporation;, Spark Therapeutics Inc, Gilead Lifesciences Inc, MEDIPOST;, PHARMICELL Co Ltd”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Advanced Therapy Medicinal Products Market Research Report |
| By Therapy Type | Cell, CAR-T, Stem Cell Therapy, Gene |
| By Companies | Organogenesis Inc, JCR Pharmaceuticals Co Ltd, Celgene Corporation, Novartis AG, UniQure NV, Kolon TissueGene Inc, Bluebird Bio Inc, Vericel Corporation;, Spark Therapeutics Inc, Gilead Lifesciences Inc, MEDIPOST;, PHARMICELL Co Ltd |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 243 |
| Number of Tables & Figures | 171 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Advanced Therapy Medicinal Products Market Report Segments:
The market is segmented by Therapy Type (Cell, CAR-T, Stem Cell Therapy, Gene).
Advanced Therapy Medicinal Products Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Advanced Therapy Medicinal Products Market
Overview of the regional outlook of the Advanced Therapy Medicinal Products Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Advanced Therapy Medicinal Products Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Advanced Therapy Medicinal Products Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Cell
2. CAR-T
3. Stem Cell Therapy
4. Gene
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Advanced Therapy Medicinal Products Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Advanced Therapy Medicinal Products Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Advanced Therapy Medicinal Products Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Advanced Therapy Medicinal Products Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Advanced Therapy Medicinal Products Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Advanced Therapy Medicinal Products Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Advanced Therapy Medicinal Products Market Size & Forecast, 2018-2028
4.5.1 Advanced Therapy Medicinal Products Market Size and Y-o-Y Growth
4.5.2 Advanced Therapy Medicinal Products Market Absolute $ Opportunity
Chapter 5 Global Advanced Therapy Medicinal Products Market Analysis and Forecast by Therapy Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy Type
5.1.2 Basis Point Share (BPS) Analysis by Therapy Type
5.1.3 Absolute $ Opportunity Assessment by Therapy Type
5.2 Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
5.2.1 Cell
5.2.2 CAR-T
5.2.3 Stem Cell Therapy
5.2.4 Gene
5.3 Market Attractiveness Analysis by Therapy Type
Chapter 6 Global Advanced Therapy Medicinal Products Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Advanced Therapy Medicinal Products Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Advanced Therapy Medicinal Products Analysis and Forecast
8.1 Introduction
8.2 North America Advanced Therapy Medicinal Products Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
8.6.1 Cell
8.6.2 CAR-T
8.6.3 Stem Cell Therapy
8.6.4 Gene
8.7 Basis Point Share (BPS) Analysis by Therapy Type
8.8 Absolute $ Opportunity Assessment by Therapy Type
8.9 Market Attractiveness Analysis by Therapy Type
Chapter 9 Europe Advanced Therapy Medicinal Products Analysis and Forecast
9.1 Introduction
9.2 Europe Advanced Therapy Medicinal Products Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
9.6.1 Cell
9.6.2 CAR-T
9.6.3 Stem Cell Therapy
9.6.4 Gene
9.7 Basis Point Share (BPS) Analysis by Therapy Type
9.8 Absolute $ Opportunity Assessment by Therapy Type
9.9 Market Attractiveness Analysis by Therapy Type
Chapter 10 Asia Pacific Advanced Therapy Medicinal Products Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Advanced Therapy Medicinal Products Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
10.6.1 Cell
10.6.2 CAR-T
10.6.3 Stem Cell Therapy
10.6.4 Gene
10.7 Basis Point Share (BPS) Analysis by Therapy Type
10.8 Absolute $ Opportunity Assessment by Therapy Type
10.9 Market Attractiveness Analysis by Therapy Type
Chapter 11 Latin America Advanced Therapy Medicinal Products Analysis and Forecast
11.1 Introduction
11.2 Latin America Advanced Therapy Medicinal Products Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
11.6.1 Cell
11.6.2 CAR-T
11.6.3 Stem Cell Therapy
11.6.4 Gene
11.7 Basis Point Share (BPS) Analysis by Therapy Type
11.8 Absolute $ Opportunity Assessment by Therapy Type
11.9 Market Attractiveness Analysis by Therapy Type
Chapter 12 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
12.6.1 Cell
12.6.2 CAR-T
12.6.3 Stem Cell Therapy
12.6.4 Gene
12.7 Basis Point Share (BPS) Analysis by Therapy Type
12.8 Absolute $ Opportunity Assessment by Therapy Type
12.9 Market Attractiveness Analysis by Therapy Type
Chapter 13 Competition Landscape
13.1 Advanced Therapy Medicinal Products Market: Competitive Dashboard
13.2 Global Advanced Therapy Medicinal Products Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Organogenesis Inc
13.3.2 JCR Pharmaceuticals Co Ltd
13.3.3 Celgene Corporation
13.3.4 Novartis AG
13.3.5 UniQure NV
13.3.6 Kolon TissueGene Inc
13.3.7 Bluebird Bio Inc
13.3.8 Vericel Corporation;
13.3.9 Spark Therapeutics Inc
13.3.10 Gilead Lifesciences Inc
13.3.11 MEDIPOST;
13.3.12 PHARMICELL Co Ltd
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Advanced Therapy Medicinal Products Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Advanced Therapy Medicinal Products Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Advanced Therapy Medicinal Products Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Advanced Therapy Medicinal Products Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Advanced Therapy Medicinal Products Market Size & Forecast, 2018-2028
4.5.1 Advanced Therapy Medicinal Products Market Size and Y-o-Y Growth
4.5.2 Advanced Therapy Medicinal Products Market Absolute $ Opportunity
Chapter 5 Global Advanced Therapy Medicinal Products Market Analysis and Forecast by Therapy Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapy Type
5.1.2 Basis Point Share (BPS) Analysis by Therapy Type
5.1.3 Absolute $ Opportunity Assessment by Therapy Type
5.2 Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
5.2.1 Cell
5.2.2 CAR-T
5.2.3 Stem Cell Therapy
5.2.4 Gene
5.3 Market Attractiveness Analysis by Therapy Type
Chapter 6 Global Advanced Therapy Medicinal Products Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Advanced Therapy Medicinal Products Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Advanced Therapy Medicinal Products Analysis and Forecast
8.1 Introduction
8.2 North America Advanced Therapy Medicinal Products Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
8.6.1 Cell
8.6.2 CAR-T
8.6.3 Stem Cell Therapy
8.6.4 Gene
8.7 Basis Point Share (BPS) Analysis by Therapy Type
8.8 Absolute $ Opportunity Assessment by Therapy Type
8.9 Market Attractiveness Analysis by Therapy Type
Chapter 9 Europe Advanced Therapy Medicinal Products Analysis and Forecast
9.1 Introduction
9.2 Europe Advanced Therapy Medicinal Products Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
9.6.1 Cell
9.6.2 CAR-T
9.6.3 Stem Cell Therapy
9.6.4 Gene
9.7 Basis Point Share (BPS) Analysis by Therapy Type
9.8 Absolute $ Opportunity Assessment by Therapy Type
9.9 Market Attractiveness Analysis by Therapy Type
Chapter 10 Asia Pacific Advanced Therapy Medicinal Products Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Advanced Therapy Medicinal Products Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
10.6.1 Cell
10.6.2 CAR-T
10.6.3 Stem Cell Therapy
10.6.4 Gene
10.7 Basis Point Share (BPS) Analysis by Therapy Type
10.8 Absolute $ Opportunity Assessment by Therapy Type
10.9 Market Attractiveness Analysis by Therapy Type
Chapter 11 Latin America Advanced Therapy Medicinal Products Analysis and Forecast
11.1 Introduction
11.2 Latin America Advanced Therapy Medicinal Products Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
11.6.1 Cell
11.6.2 CAR-T
11.6.3 Stem Cell Therapy
11.6.4 Gene
11.7 Basis Point Share (BPS) Analysis by Therapy Type
11.8 Absolute $ Opportunity Assessment by Therapy Type
11.9 Market Attractiveness Analysis by Therapy Type
Chapter 12 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Advanced Therapy Medicinal Products Market Size Forecast by Therapy Type
12.6.1 Cell
12.6.2 CAR-T
12.6.3 Stem Cell Therapy
12.6.4 Gene
12.7 Basis Point Share (BPS) Analysis by Therapy Type
12.8 Absolute $ Opportunity Assessment by Therapy Type
12.9 Market Attractiveness Analysis by Therapy Type
Chapter 13 Competition Landscape
13.1 Advanced Therapy Medicinal Products Market: Competitive Dashboard
13.2 Global Advanced Therapy Medicinal Products Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Organogenesis Inc
13.3.2 JCR Pharmaceuticals Co Ltd
13.3.3 Celgene Corporation
13.3.4 Novartis AG
13.3.5 UniQure NV
13.3.6 Kolon TissueGene Inc
13.3.7 Bluebird Bio Inc
13.3.8 Vericel Corporation;
13.3.9 Spark Therapeutics Inc
13.3.10 Gilead Lifesciences Inc
13.3.11 MEDIPOST;
13.3.12 PHARMICELL Co Ltd
Segments Covered in the Report
The global Advanced Therapy Medicinal Products market has been segmented based on
By Therapy Type
The global Advanced Therapy Medicinal Products market has been segmented based on
By Therapy Type
- Cell
- CAR-T
- Stem Cell Therapy
- Gene
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Organogenesis Inc
- JCR Pharmaceuticals Co Ltd
- Celgene Corporation
- Novartis AG
- UniQure NV
- Kolon TissueGene Inc
- Bluebird Bio Inc
- Vericel Corporation;
- Spark Therapeutics Inc
- Gilead Lifesciences Inc
- MEDIPOST;
- PHARMICELL Co Ltd
Our Clients
Related Reports
Some other reports from this category!
